NCT01183364

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Synta Pharmaceuticals Corp. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor malignancies. The safety and tolerability of the treatment will also be evaluated.

Conditions

• Solid Tumor Malignancies

Interventions

Type	Name	Description
DRUG	STA-9090 (ganetespib) with Docetaxel	One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.

Timeline

• Start date: 2010-07-01
• Primary completion: 2013-03-01
• Completion: 2013-05-01
• First posted: 2010-08-17
• Last updated: 2014-09-19

Locations

1 site across 1 country: United States